Medicines Articles
GlaxoSmithKline's Nucala (mepolizumab) has been approved by the U.S. Food and Drug Administration to treateosinophilic granulomatosis with polyangiitis (EGPA).
Japanese drug maker Shionogi has created an experimental compound delivered via a single-dose pill that has been shown to effectively kill the influenza (flu) virus in patients within a single day.
Mylan’s Ogivri (trastuzumab-dkst) has been approved by the U.S. Food and Drug Administration as a biosimilar to Genentech’s Herceptin (trastuzumab).
A Phase III, placebo-controlled study demonstrated both low-dose and high-dose therapy with a licensed, self-administered subcutaneous immune globulin product was efficacious and well-tolerated as maintenance treatment for patients with chronic inflammatory demyelinating polyneuropathy.
Abilify MyCite (aripiprazole tablets with sensor; Otsuka Pharmaceutical), the first digital ingestion tracking system, has been approved by the U.S. Food and Drug Administration.
CSL Behring noted the potential for fading print with more effect on the expiration dating on the patient tear-off portion of the vial label.
Researchers have found antibiotics can be counterproductive and weaken the immune system’s ability to fight off bacteria.
A nationwide epidemiological study showed cancer patients who continuously used disulfiram (Antabuse), a drug prescribed to alcoholics to prevent them from drinking, have a lower risk of death from cancer compared to those who stopped using the drug once diagnosed.
The U.S. Food and Drug Administration has approved Agios Pharmaceuticals’ Idhifa (enasidenib) to treat acute myelogenous leukemia.
The U.S. Food and Drug Administration has approved CSL Behring’s Haegarda (C1 esterase inhibitor subcutaneous [human]), the first and only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema attacks in adolescent and adult patients.
The U.S. Food and Drug Administration (FDA) has approved Privigen (immune globulin intravenous [human] 10% liquid) to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability.
The U.S. Food and Drug Administration has approved AbbieVie Inc.’s Mavyret (glecaprevir and pibrentasvir) to treat adults with certain types of hepatitis C.
